Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
102 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Smoking Cessation - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Smoking Cessation - Pipeline Review, H1 2015', provides an overview of the Smoking Cessation's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Smoking Cessation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Smoking Cessation - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Smoking Cessation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Smoking Cessation Overview 9 Therapeutics Development 10 Pipeline Products for Smoking Cessation - Overview 10 Pipeline Products for Smoking Cessation - Comparative Analysis 11 Smoking Cessation - Therapeutics under Development by Companies 12 Smoking Cessation - Therapeutics under Investigation by Universities/Institutes 15 Smoking Cessation - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Smoking Cessation - Products under Development by Companies 19 Smoking Cessation - Products under Investigation by Universities/Institutes 20 Smoking Cessation - Companies Involved in Therapeutics Development 21 Aradigm Corporation 21 Arena Pharmaceuticals, Inc. 22 Astraea Therapeutics, LLC 23 Bioprojet SCR 24 Embera NeuroTherapeutics, Inc. 25 FORUM Pharmaceuticals Inc. 26 GlaxoSmithKline plc 27 Invion Limited 28 Johnson & Johnson 29 Marinus Pharmaceuticals, Inc. 30 NAL Pharmaceuticals Ltd. 31 Pfizer Inc. 32 Royalty Pharma 33 Selecta Biosciences, Inc. 34 Targacept, Inc. 35 Zynerba Pharmaceuticals, Inc. 36 Smoking Cessation - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Combination Products 38 Assessment by Target 39 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 (oxazepam + metyrapone) - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Anatabine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 ARD-1600 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 BP-1.4979 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Drugs to Inhibit FAAH for CNS Disorders - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 encenicline hydrochloride - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 ganaxolone - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 GSK-598809 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 lorcaserin hydrochloride - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 nadolol - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 NIC7-DT - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 nicotine - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 nicotine - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Nicotine Vaccine - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 PF-05402536 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 PF-06413367 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 SEL-068 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Small Molecule for Smoking Cessation - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Small Molecule for Smoking Cessation and Appetite Suppression - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Small Molecule to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Smoking Cessation - Recent Pipeline Updates 78 Smoking Cessation - Dormant Projects 90 Smoking Cessation - Discontinued Products 91 Smoking Cessation - Product Development Milestones 92 Featured News & Press Releases 92 Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation 92 Nov 04, 2014: Lorcaserin Meets Primary Endpoint And Confirms Proof-Of-Concept As Potential Aid For Smoking Cessation In Investigational Phase II Clinical Study 93 Nov 03, 2014: Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation 94 Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform 95 May 09, 2014: Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ (lorcaserin HCl) CIV by 50% 96 Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial 96 Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL 97 Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs 98 Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint 99 Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation 99 Appendix 101 Methodology 101 Coverage 101 Secondary Research 101 Primary Research 101 Expert Panel Validation 101 Contact Us 101 Disclaimer 102
List of Tables Number of Products under Development for Smoking Cessation, H1 2015 10 Number of Products under Development for Smoking Cessation - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 13 Number of Products under Development by Companies, H1 2015 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H1 2015 15 Comparative Analysis by Clinical Stage Development, H1 2015 16 Comparative Analysis by Early Stage Development, H1 2015 17 Comparative Analysis by Unknown Stage Development, H1 2015 18 Products under Development by Companies, H1 2015 19 Products under Investigation by Universities/Institutes, H1 2015 20 Smoking Cessation - Pipeline by Aradigm Corporation, H1 2015 21 Smoking Cessation - Pipeline by Arena Pharmaceuticals, Inc., H1 2015 22 Smoking Cessation - Pipeline by Astraea Therapeutics, LLC, H1 2015 23 Smoking Cessation - Pipeline by Bioprojet SCR, H1 2015 24 Smoking Cessation - Pipeline by Embera NeuroTherapeutics, Inc., H1 2015 25 Smoking Cessation - Pipeline by FORUM Pharmaceuticals Inc., H1 2015 26 Smoking Cessation - Pipeline by GlaxoSmithKline plc, H1 2015 27 Smoking Cessation - Pipeline by Invion Limited, H1 2015 28 Smoking Cessation - Pipeline by Johnson & Johnson, H1 2015 29 Smoking Cessation - Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 30 Smoking Cessation - Pipeline by NAL Pharmaceuticals Ltd., H1 2015 31 Smoking Cessation - Pipeline by Pfizer Inc., H1 2015 32 Smoking Cessation - Pipeline by Royalty Pharma, H1 2015 33 Smoking Cessation - Pipeline by Selecta Biosciences, Inc., H1 2015 34 Smoking Cessation - Pipeline by Targacept, Inc., H1 2015 35 Smoking Cessation - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 36 Assessment by Monotherapy Products, H1 2015 37 Assessment by Combination Products, H1 2015 38 Number of Products by Stage and Target, H1 2015 40 Number of Products by Stage and Mechanism of Action, H1 2015 42 Number of Products by Stage and Route of Administration, H1 2015 44 Number of Products by Stage and Molecule Type, H1 2015 46 Smoking Cessation Therapeutics - Recent Pipeline Updates, H1 2015 78 Smoking Cessation - Dormant Projects, H1 2015 90 Smoking Cessation - Discontinued Products, H1 2015 91
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
